Loading clinical trials...
Loading clinical trials...
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
Conditions
Interventions
PRX-102 (pegunigalsidase alfa)
agalsidase beta
Locations
29
United States
UAB Medicine
Birmingham, Alabama, United States
Phoenix Children's Hospital
Phoenix, Arizona, United States
University of California Irvine Center
Orange, California, United States
University of California San Diego
San Diego, California, United States
Emory University School of Medicine
Atlanta, Georgia, United States
University of Iowa Hosptials and Clinics
Iowa City, Iowa, United States
Start Date
June 1, 2016
Primary Completion Date
October 1, 2021
Completion Date
July 1, 2022
Last Updated
September 13, 2023
NCT07382128
NCT05923788
NCT07277361
NCT04252066
NCT06776419
NCT05629559
Lead Sponsor
Protalix
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions